Preparing for the NASH epidemic: A call to action

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of NAFLD and NASH. The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United States, Europe, Asia, and Australia. Conference content was informed by the results of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD, including those with NASH. Participants identified promising approaches for clinical practice and prepared a comprehensive, unified strategy for primary care providers and relevant specialists encompassing the full spectrum of NAFLD/NASH care. They also identified specific high‐yield targets for clinical research and called for a unified, international public health response to NAFLD and NASH.

[1]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[2]  S. Asch,et al.  Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality , 2020, JAMA network open.

[3]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[4]  K. Cusi,et al.  Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. , 2020, Contemporary clinical trials.

[5]  A. Mithal,et al.  Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) , 2020, Diabetologia.

[6]  V. Wong,et al.  Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes , 2020, Hepatology communications.

[7]  D. Dieterich,et al.  Screening for Non-Alcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the U.S. is Cost Effective: A Comprehensive Cost-Utility Analysis. , 2020, Gastroenterology.

[8]  N. Byrne,et al.  The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial , 2020, Diabetes Care.

[9]  C. Mantzoros,et al.  The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease , 2020, Metabolism.

[10]  M. Stepanova,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  V. Wong,et al.  Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  T. Cotter,et al.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .

[13]  M. Clark,et al.  Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[15]  C. Thompson,et al.  Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis , 2020, Clinical endoscopy.

[16]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[17]  K. Cusi A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[18]  K. Cusi,et al.  Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? , 2020, The American journal of medicine.

[19]  K. Cusi Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes , 2020, Diabetes Care.

[20]  S. Asch,et al.  Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[21]  V. Wong,et al.  Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease , 2020, Journal of gastroenterology and hepatology.

[22]  M. Riddle,et al.  Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers , 2019, Clinical Diabetes.

[23]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[24]  F. Violi,et al.  Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  R. DeFronzo,et al.  Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents. , 2019, Endocrine reviews.

[26]  C. Mantzoros,et al.  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. , 2019, Metabolism: clinical and experimental.

[27]  R. Haidry,et al.  Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results , 2019, JHEP reports.

[28]  K. Cusi,et al.  Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.

[29]  O. Cummings,et al.  Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease , 2019, JAMA network open.

[30]  O. Cummings,et al.  Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.

[31]  L. Longworth,et al.  Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[32]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[33]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[34]  V. Wong,et al.  Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  Z. Younossi,et al.  Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease , 2019, Hepatology communications.

[36]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[37]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[38]  T. Taddei,et al.  Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. , 2019, Gastroenterology.

[39]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[41]  O. Cummings,et al.  Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis , 2020, Hepatology.

[42]  Cezary Szmigielski,et al.  Transfer learning with deep convolutional neural network for liver steatosis assessment in ultrasound images , 2018, International Journal of Computer Assisted Radiology and Surgery.

[43]  Joseph K. Lim,et al.  The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes , 2018, Clinical liver disease.

[44]  E. Speliotes,et al.  Treatment of Dyslipidemia in Common Liver Diseases , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[45]  Z. Younossi,et al.  Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) , 2018, Medicine.

[46]  L. Serfaty Management of patients with non‐alcoholic steatohepatitis (NASH) in real life , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[47]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[48]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[49]  K. Cusi,et al.  Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.

[51]  Siddharth Singh,et al.  Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[52]  Jasjit S. Suri,et al.  Extreme Learning Machine Framework for Risk Stratification of Fatty Liver Disease Using Ultrasound Tissue Characterization , 2017, Journal of Medical Systems.

[53]  V. Wong,et al.  Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population , 2017, Alimentary pharmacology & therapeutics.

[54]  K. Cusi,et al.  Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial , 2017, The Journal of clinical endocrinology and metabolism.

[55]  H. Makhlouf,et al.  Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease , 2017, Hepatology communications.

[56]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[57]  K. Cusi,et al.  Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.

[58]  F. Violi,et al.  Under-prescription of statins in patients with non-alcoholic fatty liver disease. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[59]  T. Kawaguchi,et al.  Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.

[60]  J. Gottdiener,et al.  The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[61]  K. Cusi,et al.  Pharmacological management of nonalcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.

[62]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[63]  S. Sookoian,et al.  How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? , 2016, Gastroenterology.

[64]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[65]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[66]  H. El‐Serag,et al.  Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia , 2016, Digestive Diseases and Sciences.

[67]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[68]  E. Bugianesi,et al.  Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander , 2015, Seminars in Liver Disease.

[69]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[70]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[71]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[72]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[73]  H. El‐Serag,et al.  Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting , 2015, The American Journal of Gastroenterology.

[74]  K. Cusi,et al.  The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.

[75]  H. Makhlouf,et al.  Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.

[76]  James E. Nelson,et al.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[77]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[78]  Sarah A. Moore,et al.  Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss , 2011, Gut.

[79]  O. Cummings,et al.  Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.

[80]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[81]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[82]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[83]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.